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Abstract
Background: Currently, tamoxifen and raloxifene are the only FDA-approved and USPSTF recommended
pharmacologic treatments for breast cancer chemoprevention in high-risk postmenopausal women. Despite
their widely recognized efficacy at reducing the incidence of breast cancer, the risk of potentially significant
adverse effects may limit patient allocation. Consequently, research on the efficacy of third-generation
aromatase inhibitors (AIs) as breast cancer preventives has emerged, especially since their value as adjuvant
and combination therapy for breast cancer is well-established. The safety profile of anastrozole and
exemestane potentially provide an appealing alternative to postmenopausal patients with a higher risk of
developing breast cancer. Studies have successfully demonstrated the efficacy of AIs at reducing the incidence
breast cancer, and further research will help to validate the FDA-approval of AIs for this indication.
Methods: An exhaustive search of medical literature included MEDLINE, Web of Science, CINAHL, and the
National Institute of Health Clinical Trials using the key words: aromatase inhibitors, anastrozole, letrozole,
exemestane, and chemoprevention. Relevant articles were critically appraised and GRADE was used for
qualitative assessment.
Results: An extensive literary search rendered 262 relevant articles from January 2000 to February 2014.
After screening several articles, two randomized control trials met inclusion criteria. The NIH clinical trials
site yielded 36 results, and one trial met inclusion criteria. The LIBER trial, listed under NCT00673335, is in
Phase III with a predicted completion date of February 2017.
Conclusion: Third generation AIs, such as anastrozole and exemestane, are very effective at reducing the
incidence of invasive breast cancer, ductal carcinoma in situ, and certain tumors in high-risk postmenopausal
women. Although both AIs demonstrate adverse effects, their overall safety profiles may be more favorable
than other pharmacologic chemoprevention alternatives. More research, larger scale studies, and a longer
follow-up after concluding treatment will be valuable to the prospective FDA-approval of AIs in breast cancer
prevention.
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Abstract     
 
Background: Currently, tamoxifen and raloxifene are the only FDA-approved and USPSTF 
recommended pharmacologic treatments for breast cancer chemoprevention in high-risk 
postmenopausal women. Despite their widely recognized efficacy at reducing the incidence 
of breast cancer, the risk of potentially significant adverse effects may limit patient 
allocation.  Consequently, research on the efficacy of third-generation aromatase inhibitors 
(AIs) as breast cancer preventives has emerged, especially since their value as adjuvant and 
combination therapy for breast cancer is well-established. The safety profile of anastrozole 
and exemestane potentially provide an appealing alternative to postmenopausal patients with 
a higher risk of developing breast cancer.  Studies have successfully demonstrated the 
efficacy of AIs at reducing the incidence breast cancer, and further research will help to 
validate the FDA-approval of AIs for this indication.   
 
Methods:  An exhaustive search of medical literature included MEDLINE, Web of Science, 
CINAHL, and the National Institute of Health Clinical Trials using the key words: aromatase 
inhibitors, anastrozole, letrozole, exemestane, and chemoprevention.  Relevant articles were 
critically appraised and GRADE was used for qualitative assessment.  
 
Results:  An extensive literary search rendered 262 relevant articles from January 2000 to 
February 2014. After screening several articles, two randomized control trials met inclusion 
criteria. The NIH clinical trials site yielded 36 results, and one trial met inclusion criteria. 
The LIBER trial, listed under NCT00673335, is in Phase III with a predicted completion date 
of February 2017. 
 
Conclusion:  Third generation AIs, such as anastrozole and exemestane, are very effective at 
reducing the incidence of invasive breast cancer, ductal carcinoma in situ, and certain tumors 
in high-risk postmenopausal women. Although both AIs demonstrate adverse effects, their 
overall safety profiles may be more favorable than other pharmacologic chemoprevention 
alternatives.  More research, larger scale studies, and a longer follow-up after concluding 
treatment will be valuable to the prospective FDA-approval of AIs in breast cancer 
prevention. 
 
Keywords:  aromatase inhibitors, anastrozole, letrozole, exemestane, chemoprevention 
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The Efficacy of Third Generation Aromatase Inhibitors in Breast Cancer 
Chemoprevention 
BACKGROUND 
 Currently, tamoxifen and raloxifene are the only FDA-approved1,2 and USPSTF 
recommended3 treatments for breast cancer chemoprevention in high-risk postmenopausal 
patients. Albeit their efficacy as widely recognized preventive agents, neither comes without 
statistically significant adverse events, such as venous thromboembolism, endometrial 
cancer, or stroke.4-6 
 Third generation aromatase inhibitors (AIs) have proven not only their efficacy as 
adjuvant and combination treatment of breast cancer, but also exhibit a favorable safety 
profile.6,7 Despite their association with accelerated bone loss and prolonged use,7,8 AIs 
provide a potentially more appealing alternative to postmenopausal patients who are unable 
to take selective estrogen receptor modulators (SERMs), decline the use of SERMs due to 
significant adverse effects or other reasons, or are considering surgical options for breast 
cancer prophylaxis.  The favorable advent of AIs in the chemopreventive setting has even led 
the American Society of Clinical Oncology (ASCO) to refine treatment recommendations.9 
 Based on the current ASCO guidelines for pharmacologic intervention for breast 
cancer risk reduction, the recommendation for third generation aromatase inhibitors extends 
only to exemestane in the preventive setting.  As of 2013, the new recommendation for 
exemestane is that it should be considered a breast cancer risk-reducing alternative to 
tamoxifen and raloxifene in postmenopausal patients who have a higher risk of developing 
breast cancer, especially those who are estrogen-receptor positive or have a history of lobular 
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carcinoma in situ or atypical hyperplasia.  The benefits and risks of exemestane should be 
discussed with the patient, as should the use of any preventive pharmacologic agent.9  
 The purpose of this systematic review is to investigate the efficacy of third generation 
aromatase inhibitors as chemopreventive agents in postmenopausal women who have a 
greater risk of developing breast cancer.  
METHODS 
 An exhaustive search of medical literature included MEDLINE, Web of Science, 
CINAHL, and the National Institute of Health Clinical Trials registry using key words: 
aromatase inhibitors, anastrozole, letrozole, exemestane, and chemoprevention.  Inclusion 
criteria were clinical studies on high-risk post-menopausal women, using aromatase 
inhibitors, evaluating chemoprevention, measuring incidence of breast cancer, and published 
in the English language.  Exclusion criteria consisted of studies containing adjuvant or 
combination therapy or concomitant hormone-replacement therapy. Once pertinent articles 
were identified, the bibliographies were thoroughly examined.  Articles that met inclusion 
criteria were critically appraised and Grading of Recommendations, Assessment, 
Development and Evaluations (GRADE) was used to qualitatively assess each study.10 
RESULTS 
 An extensive literary search of various databases initially rendered 262 relevant 
articles from January 2000 to February 2014. After omitting duplicates and screening the 
remaining articles, two randomized control trials11,12 were identified as meeting eligibility 
criteria. A search of the National Institute of Health Clinical Trials database yielded 36 active 
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clinical trials, with one that has yet to be published.13 Tables I & II provide a summary of 
findings and quality assessment of reviewed articles. 
IBIS-II Trial 
 The International Breast cancer Intervention Study II (IBIS-II)11 is a randomized, 
double-blind, placebo-controlled trial that evaluated the efficacy and safety of anastrozole as 
a breast cancer preventive in high-risk postmenopausal women. Over a nearly 10-year period 
beginning in 2003, a total of 3864 eligible participants were selected. Women were 
postmenopausal, aged 40-70 years old, and had a greater risk of developing breast cancer. 
Those considered high-risk included women aged 40-44 years with four times the relative 
risk, aged 45-60 years with greater than twice the relative risk, those aged 60-70 years with 
greater than 1.5 times the relative risk of breast cancer, or women who had a 10-year risk of 
breast cancer greater than 5% based on the Tyrer-Cuzick model.11 
 Women excluded from the study were premenopausal, had a personal history of 
breast or other cancer, used hormone replacement therapy for greater than 6 months, had a 
prophylactic mastectomy, had severe osteoporosis, had a less than 10-year life expectancy, 
had a history of gluten and/or lactose intolerance, intended to continue hormone replacement 
therapy, or had a physiological or psychological reason that would confound the trial.  The 
study took place throughout 153 centers in 18 countries. Over a period of 5 years, 1914 
randomized participants were given 1 mg of anastrozole orally per day.11 
 The primary endpoint was occurrence of breast cancer. Secondary endpoints included 
estrogen-receptor positive breast cancer, other cancers, cardiovascular disease, death 
contributed to breast cancer or other causes, and adverse episodes.  Endpoints were 
monitored via interval clinic visits, a mammogram at baseline and then at a minimum of 
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every 2 years, baseline dual energy x-ray absorptiometry scan and spinal radiographs, and 
blood work for possible biomarkers at baseline, 1 year, and 5 years.11 
 Cuzick et al11 concluded that anastrozole is effective at reducing the incidence of 
invasive breast cancer and ductal carcinoma in situ (DCIS) (HR 0.47, 95% CI 0.32-0.68; 
p<0.0001; NNT =36 in 7 years). The authors determined that anastrozole was particularly 
effective at reducing the incidence of high-grade invasive breast cancer (HR 0.35, 95% CI 
0.16-0.74) when compared to low-grade invasive breast cancer (HR 0.86, 95% CI 0.31-2.38). 
Cuzick et al further reported that anastrozole was effective at reducing the incidence of 
estrogen-receptor positive tumors (HR 0.42, 95% CI 0.25-0.71) when compared to placebo.11 
 The most commonly reported side effects included vasomotor (RR 1.15, 95% CI 
1.08-1.22) and musculoskeletal symptoms (RR 1.10, 95% CI 1.06-1.16), which were more 
prevalent in the anastrozole group versus the placebo group. Other symptoms significant in 
the anastrozole group included vaginal dryness, hypertension, influenza, and otitis media 
(95% CI, RR 1.19 [1.03-1.37], 1.64 [1.18-2.28], 2.11 [1.06-4.19], and 3.04 [1.21-7.64], 
respectively).  Although more hypertensive events occurred in the anastrozole group, authors 
reported no discernible difference in cardiovascular or stroke events between the groups.  
Furthermore, Cuzick et al11 conveyed no dissimilarity in the event of fractures when 
comparing the two groups (RR 1.11, 95% CI 0.90-1.38), despite 16% of participants 
simultaneously taking a bisphosphonate (330 [17%] in anastrozole group versus 297 [15%] 
in placebo group).11 
 Regarding adherence, authors projected that 68% of the anastrozole group and 72% 
of the placebo group had completed the entire 5-year treatment period.  Reasons listed for 
early termination of treatment were adverse effects (375 [20%] in anastrozole group; 298 
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[15%] in placebo group) and the elective withdrawal of participants from treatment (94 [5%] 
in anastrozole group; 98 [5%] in placebo group).11 
 Cuzick et al11 endorse the use of anastrozole as a breast cancer preventive in high-risk 
postmenopausal women. 
MAP.3 Trial 
 The NCIC Clinical Trials Group Mammary Prevention.3 (MAP.3)12 is a randomized, 
double-blind, placebo-controlled trial that evaluated the efficacy and safety of exemestane as 
a breast cancer preventive in high-risk postmenopausal women. Over a nearly 6-year period 
that began in 2004, a total of 4560 participants were recruited. Participants eligible for the 
trial included postmenopausal women aged 35 or older and at least one qualifying risk factor: 
aged 60 or older, Gail score >1.66%, personal history of lobular carcinoma in situ or atypical 
ductal hyperplasia, or ductal carcinoma in situ treated with mastectomy. Ineligible 
participants included carriers of the BRCA1 or BRCA2 gene, premenopausal, history of 
cancer, uncontrolled thyroid disease, or chronic liver disease.12 
 The study took place in the United States, Canada, Spain, and France. Over a median 
follow-up period of almost 3 years, 2285 randomly assigned participants were given 25mg of 
exemestane, taken orally each day.  The primary endpoint was occurrence of invasive breast 
cancer. Secondary endpoints included invasive breast cancer with associated DCIS, estrogen-
receptor negative breast cancer, lobular carcinoma in situ (LCIS), atypical lobular 
hyperplasia (ALH), number of clinical breast biopsies, cardiovascular events that also 
included those resulting in death, clinical fractures, other cancers, development of side 
effects, and menopause-specific quality of life (QOL).12 
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 Screening for breast-related events included interval clinical evaluations at 6 months 
and then each year, plus annual mammograms. Study data was reviewed every 6 months by 
an independent safety and data monitoring committee.12 
 After the median follow-up of 35 months, the trial proved that exemestane is effective 
at reducing the incidence of invasive breast cancer and DCIS (HR 0.47, 95% CI 0.27-0.79; 
p<0.004; NNT = 94 in 3 years).  Goss et al12 noted a decrease in the incidence of 
precancerous breast events, such as HER2-neu positive tumors (HR N/A) and estrogen-
receptor positive tumors (HR 0.27, 95% CI 0.12-0.60, p<0.001), when compared to placebo. 
The total number of breast-related events was 66, and authors reported a 65% relative 
incident reduction of invasive breast cancers, from 0.55% to 0.19%.12  
 The most commonly reported adverse effects were vasomotor and joint-related 
symptoms. Symptoms more prevalent in those taking exemestane versus placebo included 
hot flashes, fatigue, sweating, arthritis, and arthralgia (p<0.001, p=0.03, p=0.046, p=0.01, 
p=0.04, respectively).  Goss et al12 also reported that no critical side effects, such as fractures, 
end-organ damage, other cancers, or death were directly contributed to exemestane.12 
 Upon closure of the trial, 32.8% of participants in the exemestane group and 28.7% of 
participants in the placebo group had discontinued the medication. Goss et al12 remarked 
notable reasons for untimely treatment cessation included completion of the drug, adverse 
effects, and patient refusal.12 
 Goss et al12 concluded that exemestane is effective at reducing the incidence of 
invasive breast cancer in postmenopausal women with a higher risk than the general 
population. The MAP.3 trial determined that key components of this study were the risk-to-
benefit ratio and safety profile of exemestane.12 
12 
 
LIBER Trial: Phase III 
 The purpose of the LIBER trial13 is to determine the efficacy of letrozole versus 
placebo in breast cancer prevention in postmenopausal women with the BRCA1 or BRCA2 
gene.  The projected active treatment period is 5 years, and the intended observation period 
for long-term effects after concluding treatment is 5 years.13  
 Eligible participants must be postmenopausal, aged 40-69 years or older, ECOG or 
WHO performance status 0-1, normal complete blood count and labs as specified by certain 
criteria, or no history of osteoporosis or fractures within the past 2 years of enrollment.   
Exclusion criteria are personal history of invasive cancer within the past 5 years, history of 
cardiovascular disease such as myocardial infarct or ischemia, hypersensitivity to letrozole, 
hepatic or renal insufficiency, prior hormone therapy in the past year, or any other 
psychological or social reason that would be interfere with the study.13 
 The LIBER trial is currently in Phase III with a predicted completion date of February 
2017.13  
DISCUSSION 
 Third generation aromatase inhibitors, specifically anastrozole and exemestane, are 
effective at reducing the incidence of invasive breast cancer and DCIS in high-risk 
postmenopausal women.  According to the IBIS-II trial,11 47% of the placebo group 
developed invasive breast cancer or DCIS compared to the anastrozole group (HR 0.47, 95% 
CI [0.32-0.68]).  Of particular significance, 35% of the placebo group developed a high-
grade invasive tumor (HR 0.35, 95% CI [0.16-0.74]), and 42% of the placebo group 
developed an estrogen-receptor positive invasive tumor (HR 0.42, 95% CI [0.25-0.71]) when 
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compared to the anastrozole group. Overall, of 36 people treated with anastrozole in a 7-year 
period, one person will develop invasive breast cancer or DCIS.  
 The MAP.3 trial12 demonstrated the significant efficacy of exemestane in breast 
cancer prevention.  In the placebo group, 47% developed invasive breast cancer or DCIS 
compared to the exemestane group (HR 0.47, 95% CI [0.27-0.79]).  Additionally, 36% of the 
placebo group developed precancerous tumors such as LCIS, ADH, and ALH (HR 0.36, 95% 
CI [0.11-1.12]). Overall, one person out of 94 treated with exemestane will develop invasive 
breast cancer or DCIS in a 3 year period.   
 Additionally, both trials11,12 also demonstrate the relative safety of aromatase 
inhibitors, especially with regard to fracture risk and concomitant use of bisphosphonates. 
 Although the trials11,12 have proven the efficacy of anastrozole and exemestane as 
breast cancer chemopreventive agents in high-risk postmenopausal women, each have 
limitations. The most profound limitation of both studies is the loss to follow-up: 30% of 
participants in the IBIS-II trial11 and 30.3% of participants in the MAP.3 trial12 (Tables I & 
II).  Further limitations of the MAP.3 trial12 included a lack of precision, considering only 66 
breast-related events, a median follow-up of only 35 months, and the amount of participants 
who received exemestane was less than anticipated.12 The limitations of each trial, and the 
lack of precision in the MAP.3 study were factored into the GRADE qualitative assessment 
and have been downgraded as deemed necessary (Table II). 
 Further GRADE analysis10 of the IBIS-II and MAP.3 studies11,12 did not yield any 
serious concerns with inconsistency, indirectness, or risk of bias.  Although the GRADE of 
the IBIS-II trial11 is considered “moderate” and the MAP.3 trial12 is considered “low,” the 
overall quality of evidence is modestly supportive. Clinicians should be encouraged by the 
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fact that AIs are efficacious at reducing the incidence of breast cancer in postmenopausal 
women at a higher risk. 
  The results of the IBIS-II and MAP.3 trials11,12 and the anticipated results of the 
LIBER trial13 are encouraging for the future of AIs as chemopreventive agents in high-risk 
postmenopausal women. Recommendations for future study of aromatase inhibitors include 
investigating a larger outcome and evaluating the lasting effects of treatment, including their 
long-term efficacy and safety at reducing the incidence of breast cancer after the treatment 
period has concluded. 
CONCLUSION 
 Third-generation aromatase inhibitors, such as anastrozole and exemestane, are 
remarkably effective at reducing the incidence of invasive breast cancer and DCIS in high-
risk postmenopausal women.  Anastrozole demonstrates extended efficacy at reducing the 
incidence of high-grade and estrogen-receptor positive invasive tumors, while exemestane 
also proves to be effective at decreasing the number of HER2-neu positive and estrogen-
receptor positive tumors.  Although both anastrozole and exemestane exhibit adverse effects, 
the overall safety profile of each may be more favorable than other chemoprevention 
alternatives.  Further research on AIs, such as the publication of the LIBER trial, 
investigating larger scale studies, and evaluating the lasting effects of treatment after the 
established 5-year completion, will substantiate the evidence for prophylactic use of AIs in 
breast cancer prevention. 
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Table I. Summary of Findings 
Study 
No. of Participants Age of 
Participants 
Loss to 
Follow-Up 
Effect Duration of 
Follow-Up 
(median) 
Control 
Group 
Placebo 
Group HR (95% CI)
 J NNT 
C
uz
ic
k 
et
 a
l11
 
IBIS-II: 
Anastrozole 1914 1937 55-64 yrs 1155 (30%) 0.47 (0.32-0.68) 
36 in 
7 yrs 5 years 
G
os
s e
t a
l12
 
MAP.3: 
Exemestane 2285 2275 37-90 yrs 1381 (30.3%) 0.47 (0.27-0.79) 
94 in 
3 yrs 35 months 
JHazard Ratio: Invasive breast cancer and DCIS 
 
Table II. GRADE Quality Assessment of Reviewed Articles 
Studies Design Limitations Inconsistency Indirectness Imprecision Risk of Bias Quality Importance 
Incidence of Breast Cancer 
Cuzick et al11 RCT SeriousG Not serious Not serious Not serious Not serious MODERATE Critical 
Goss et al12 RCT SeriousG Not serious Not serious SeriousJ Not serious LOW Critical 
GDowngraded for large loss to follow-up 
JDowngraded due to duration of follow-up (3 years) and amount of breast-related outcomes (66) 
 
 
 
 
